CSF3 and plasma cell myeloma: As for ASCT, a recent study from an Italian transplant center have explored the use of biosimilar Peg-filgrastim among multiple myeloma patients undergoing ASCT suggesting a substantial superimposable efficacy and safety compared to other G-CSFs (originator Peg-filgrastim and biosimilar short-acting filgrastim) [11].